SCHEMBL20544892

SCHEMBL20544892

O=C(CCCCCSc1ccc(F)cc1)Nc1cc(-c2ccccc2)ccc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 13/20 0.58
MEN1 O00255 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
HDAC2 Q92769 6/20 0.50
HDAC3 O15379 5/20 0.49
HDAC6 Q9UBN7 6/20 0.48
HDAC4 P56524 4/20 0.48
HDAC7 Q8WUI4 4/20 0.48
HDAC10 Q969S8 4/20 0.48
HDAC11 Q96DB2 4/20 0.48
HDAC8 Q9BY41 4/20 0.48
HDAC9 Q9UKV0 4/20 0.48
HDAC5 Q9UQL6 4/20 0.48
APOBEC3G Q9HC16 2/20 0.46
KDM4E B2RXH2 1/20 0.46
APOBEC3A P31941 1/20 0.46
GFER P55789 1/20 0.46
ASAH1 Q13510 1/20 0.45
HCAR2 Q8TDS4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20544899 0.85 RAB9A (0.71) HDAC1MEN1RAB9AKMT2AHDAC2
SCHEMBL20545469 0.84 GAA (0.58) HDAC1MEN1RAB9AKMT2AHDAC2
SCHEMBL20545258 0.81 HTR1A (0.48) HDAC1MEN1RAB9AKMT2AHDAC2
SCHEMBL21368982 0.81 ASAH1 (0.54) HDAC1MEN1RAB9AKMT2AHDAC2
SCHEMBL6386256 0.79 HDAC1 (0.72) HDAC1HDAC2HDAC3HDAC6HDAC4
SCHEMBL31734083 0.78 HDAC1 (0.53) HDAC1MEN1RAB9AKMT2AHDAC2
SCHEMBL17045915 0.78 HDAC1 (0.53) HDAC1MEN1RAB9AKMT2AHDAC2
SCHEMBL15694844 0.78 RAB9A (0.74) HDAC1MEN1RAB9AKMT2AHDAC2
SCHEMBL20545185 0.78 HDAC3 (0.66) HDAC1MEN1RAB9AKMT2AHDAC2
SCHEMBL20545261 0.78 HDAC3 (0.66) HDAC1MEN1RAB9AKMT2AHDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-07-21 US disclosed
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF T 2020-07-02 US disclosed
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF T 2020-07-02 US disclosed
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-04-21 US disclosed
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-04-21 US disclosed
US-10160705-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2018-12-25 US disclosed
US-20180312455-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2018-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160705-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury HDAC1, HDAC9, HDAC11 HDAC1 1/4885MEN1 4549/4885RAB9A 1305/4885
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma MMP8, PLAU, KLKB1 HDAC1 1068/4885MEN1 3286/4885RAB9A 2356/4885
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury HDAC1, HDAC9, HDAC11 HDAC1 1/4885MEN1 4549/4885RAB9A 1305/4885
US-20180312455-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 HDAC1 1/4885MEN1 4549/4885RAB9A 1305/4885
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 HDAC1 1/4885MEN1 4549/4885RAB9A 1305/4885
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma HDAC1, HDAC2, HDAC4 HDAC1 1/4885MEN1 4252/4885RAB9A 3691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.